Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Gemella" patented technology

Gemella is a genus of Gram-positive bacteria that thrive best at high partial pressure of CO₂.

Application of lactobacillus delbrueckii

PendingCN110024850AGood at inhibiting harmful bacteriaImprove the preservation effectFruit and vegetables preservationLactobacillusBacteria coliformsFruits and vegetables
The embodiment of the invention discloses application of lactobacillus delbrueckii. The application is characterized in that the lactobacillus delbrueckii is applied to inhibition of mesophilic aerobic bacteria, saccharomycetes, mould and coliform bacteria. The lactobacillus delbrueckii has a preservation number of CGMCC No.11247. In the lactobacillus delbrueckii activating process, bacteriocin can be generated and can remarkably inhibit the mesophilic aerobic bacteria, saccharomycetes, mould and coliform bacteria on the surfaces of fruits and vegetables, so that the preservation effect of thefruits and vegetables can be improved. Furthermore, secondary metabolites of the lactobacillus delbrueckii can be biodegraded and digested by human bodies, and are healthy and harmless to human bodies.
Owner:LANZHOU UNIVERSITY

Method for diagnosing migraine using oral microbiome

PCT designated stageWO2026024115A1Microbiological testing/measurementCardiobacterium valvarumGemella haemolysans
The present disclosure relates to a method for providing information for diagnosing migraine and, more specifically, to a method for accurately and quickly diagnosing migraine without pain or discomfort to a patient, the method comprising a step of measuring the relative abundance of at least one bacterium selected from the group consisting of Gemella haemolysans, Centipeda periodontii, Cardiobacterium valvarum, Catonella morbi, and Selenomonas noxia in a biological sample.
Owner:IND ACADEMIC COOP FOUND YONSEI UNIV

Biomarker for predicting severe condition of COVID-19 patient and application of biomarker

The invention discloses a biomarker for predicting severe treatment of a COVID-19 patient and application of the biomarker, and relates to the technical field of biomedicine. According to the invention, a COVID-19 patient severity prediction or auxiliary prediction model which is obtained by constructing biomarkers including Gemelia haemolsos, Streptococcus sp.A12, Fusobacterium pseudoperiodontium, Gemelia mollissima, Villonella atypical, Villonella rogosa and Prevotella melaninogena is found, the model is used for predicting and evaluating the severity of the COVID-19 patient, the sensitivity is high, and the specificity is good. The invention further discloses a method for predicting and evaluating the severity of the COVID-19 patient severity, and the method has the advantages that the method can be used for predicting and evaluating the severity of the COVID-19 patient severity;
Owner:SUN YAT SEN UNIVERSITY SHENZHEN +1

Method for the early detection of vomit behaviour in patients with eating disorders

PCT designated stage expiredWO2024245802A1Microbiological testing/measurementSaliva sampleAggregatibacter
The present invention refers to the use of bacteria present in the oral microbiota of a patient with Eating Disorders (EDs) as diagnostic marker of the presence of vomiting behaviour in the patient. Specifically, the bacteria belong to one or more genera selected from Granulicatella and Actinomyces, and, optionally Bulleidia, Veillonella, Oribacterium, Porphyromonas, Gemella, Campylobacter and Aggregatibacter. Further, the present invention refers to the method for the detection of vomiting behaviour in a patient with EDs, comprising the steps of i) obtaining a saliva sample from the patient, ii) determining the bacteria profile of the saliva sample and comparing to the bacteria profile of a control sample, and iii) detecting whether there are statistically significant differences between both bacteria profiles, attributing such statistically significant differences to a vomiting behaviour. Finally, the invention refers to an in vitro kit adapted to implement the method of the invention.
Owner:CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED MP (CIBER) +4

Bacterial microbiome used as marker for gastric cancer diagnosis and application of bacterial microbiome

The invention discloses a bacterial microbiome serving as a marker for gastric cancer diagnosis and application of the bacterial microbiome, the bacterial microbiome is selected from bacteria at the level or above, and the marker is one or more of CandidatusOdyssella, Gemella, Veillonella, Ferritrophium, Prevotella, Lentimicrobium, Woodsholea, Streptococcus, Hyphomicrobium, Terrimonas, Allobaculum and Sulfurimonas. The invention further discloses the application of the bacterial microbiome as the marker for gastric cancer diagnosis. By using the marker, GC can be accurately and reliably screened and diagnosed.
Owner:NANJING DRUM TOWER HOSPITAL